Press releases - Québec International would like to take this opportunity to express its solidarity with all of Quebec City's Muslim community in the wake of last night's tragic events at the local Islamic cultural centre (Centre culturel islamique de Québec).
News - Nordic Life Science Pipeline Inc. («Nordic») is proud to announce the launch of SQIN™ Body and SQIN ™ Hand & Foot, its first two cosmeceutical products to reach market. SQIN™ constitutes a unique line of skin products specifically designed and adapted for persistent and severe chronic dry skin problems found often in people suffering of paralysis or mobility impairment attributed to age, amputation, neurological and musculoskeletal problems or metabolic disorders.
News - The technology revolution that has taken hold in Québec City over the past few decades has spawned a number of life sciences success stories, paving the way for the development of a wide array of technologies in numerous fields. The life sciences sector alone employs nearly 6,000 people in Québec City and generates annual sales of over $1 billion, according to figures compiled by Québec International.c
News - The scientist who led the work to develop the Ebola drug ZMapp is going to be leaving the National Microbiology Laboratory in Winnipeg. Dr. Gary Kobinger is the lab's chief of special pathogens, heading a team that works on some of the world's worst disease threats. Kobinger will be vacating that position next June to become the director of the Centre for Research in Infectious Diseases at Laval University in Quebec City.
News - Medicago, a major Canadian biotech company and an international leader in the development and production of plant-based vaccines and therapeutics, is proud to announce that Quebec City will be home to its new production complex. The $245 million project will create 200 new high-skilled jobs by 2019, adding to the team of 180 employees already working at Medicago’s Quebec City office and laboratories. The project is expected to generate more than $461 million in direct and indirect economic benefits over the next five years.
News - B-TEMIA Inc., a market leader in human augmentation, announced the closing of a private placement with a group of Canadian private investors and the Toronto-based private healthcare fund, Epic Capital Management Inc., a boutique investment firm focused on Canadian small and mid-cap securities. This new financing confirms a 60% increase in B-TEMIA's value creation over the last year.
News - TELUS is investing $64 million in new communications infrastructure across the Greater Québec City area this year to connect thousands of homes in Saint-Raymond directly to TELUS’ fibre optic network, enhance wireless capacity and speed, and extend the reach of TELUS Health technology.
News - Nordic Life Science Pipeline is proud to launch the recruitment and testing of volunteers for the double-blind, randomized clinical study (phase II) of SQIN™, the first dermatologic product of its new biocosmeceutical division called NORBIODERM. NORDIC intends to be first in specializing on dermatological products for chronic dry skin conditions (xerosis) typically experienced by individuals with paralysis and/or mobility impairment. Pending upon these results, commercialization of SQIN™ may be announced as early as Q3-2015.
News - handyem Inc., a manufacturer of personal and portable flow cytometers announces the commercial launch of the HPC-150 personal cytometer for life science research, bioprocessing, water quality and many other applications. The HPC-150 flow cytometer from handyem is portable and rugged. Its reliable fiber-optics flow cell eliminates the need for periodic laser alignment and reduces by an order of magnitude the amount of sheath fluid normally required by conventional flow cytometers.
News - Opsens Inc. ("Opsens" or the "Company") (TSXV: OPS) (OTCQX: OPSSF) announces that its common shares began trading under the ticker symbol "OPSSF" on the OTCQX marketplace in the United States, effective today. OTCQX, operated by OTC Markets Group Inc., offers the best informed and most efficient trading for established, global and growth companies. Opsens' shares will continue trading on the TSX Venture Exchange under the ticker symbol "OPS."